IL-NIQ
NIQ, the global leader in consumer intelligence, is pleased to announce the NIQ Connect platform capabilities have now expanded to use Snowflake Secure Data Sharing. This capability marks a significant milestone for NIQ's Connect platform, empowering customers in 84 global markets with enhanced data-sharing capabilities and seamless real-time data access. As a result, this can eliminate processing and loading wait times, delivering unparalleled efficiency and agility in a complex consumer landscape.
“By extending their ability to effortlessly access global, omnichannel data, we can empower clients to uncover new pathways to growth even within a very complex consumer landscape,” said Troy Treangen, Chief Product Officer at NIQ. “Innovation is our compass, and our commitment to reengineering the Connect platform has charted a new course. Our strategic investments have allowed us to unlock the power of modern data sharing capabilities, guiding our clients towards a brighter, data-driven future."
NIQ Connect is a crucial asset for enterprises, enabling them to harness their data across all facets of their organization. With integrated data assets, businesses can readily identify emerging trends, pinpoint performance gaps, and respond swiftly to growth opportunities. This global collaboration is poised to unveil novel insights, leading to a deeper understanding of customers' behavior and preferences.
Additional highlights of the NIQ’s Connect platform integration with Snowflake’s Retail Data Cloud include:
- Seamless Data Integration: Companies will benefit from the seamless integration of NIQ's rich consumer and market data into Snowflake’s environment. This integration simplifies access to vast data sources, and drives significant speed improvements for our clients when accessing data.
- Secure Data Sharing: Availability through Snowflake facilitates near real-time data sharing, enabling businesses to access and query NIQ's data instantaneously. This dynamic exchange of information empowers organizations to stay ahead in today's fast-paced business landscape.
- Scalability and Flexibility: NIQ’s Connect platform with Snowflake Secure Data Sharing is designed to scale effortlessly with the growing data needs of businesses. Whether a company is a startup or a Fortune 500 enterprise, this provides the flexibility to adapt and grow in a rapidly changing environment.
- Enhanced AI and Machine Learning Capabilities: Businesses can leverage advanced analytics and machine learning within Snowflake's platform to derive actionable insights from NIQ's data. This synergy fosters innovation, enabling companies to make data-driven decisions with precision.
- Data Security and Compliance: Both NIQ and Snowflake prioritize data security and compliance. The joint solution ensures that sensitive data is protected providing peace of mind to businesses and their customers while enabling them to meet evolving regulatory requirements.
“NIQ is committed to helping companies become more agile at a time when being able to move quickly based on accurate data is paramount,” Treangen added. “This innovative data-sharing approach will provide Connect customers a competitive advantage today and be better prepared for the future. We are modernizing every level of our Connect platform, and we are excited about the enhancements to help our clients thrive.”
“As an incumbent leader in retail and consumer insights, NIQ has been a staple in the retail industry for delivering data that give a competitive edge to retailers and consumer product companies,” said Rosemary DeAragon, Global Head of Retail and Consumer Goods at Snowflake. “We are so excited to bring together the full power of the Snowflake Retail Data Cloud and the NIQ Connect platform, allowing global frictionless access to critical data through Snowflake data sharing.”
NIQ is dedicated to fostering innovation and enabling organizations to thrive in a data-driven world. The collaboration between NIQ and Snowflake represents a transformative step in the world of data sharing and will shape the future of data analytics. As organizations increasingly recognize the value of data in their operations, allowing them to exchange insights seamlessly and efficiently will empower them to unlock new opportunities and navigate the data landscape with ease.
For more information about this NIQ Connect and its benefits, please visit https://nielseniq.com/global/en/solutions/nielseniq-connect/.
About NIQ
NIQ is the world’s leading consumer intelligence company, delivering the most complete understanding of consumer buying behavior and revealing new pathways to growth. In 2023, NIQ combined with GfK, bringing together the two industry leaders with unparalleled global reach. With a holistic retail read and the most comprehensive consumer insights—delivered with advanced analytics through state-of-the-art platforms—NIQ delivers the Full ViewTM.
NIQ, is an Advent International portfolio company with operations in 100+ markets, covering more than 90% of the world’s population. For more information, visit NIQ.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230919644465/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
Over 30 Million Users Benefit From Ant International’s Bettr Credit Tech Solutions18.11.2025 04:35:00 CET | Press release
Powering the Next Wave of MSME Growth with Digital Platforms in Emerging MarketsThere was a threefold year-on-year increase in eligible customers reached through partners using Bettr's credit tech solutions by the end of October 2025.The solution features an AI-driven, alternative-data-powered credit engine that can help partner platforms to cut credit policy deployment from weeks to minutes.Partnership with Dock, a leading Brazilian payments and banking technology provider, will expand the deployment of Bettr’s credit tech solutions. Bettr, a leading provider of inclusive financial services and technology business under Ant International, today announced the launch of its proprietary tailored, one-stop credit tech solutions designed to help digital platforms build and scale their lending businesses to better serve micro, small and medium enterprises (MSMEs) in emerging markets. Bettr's credit tech solutions supported over 30 million customers to gain access to credit services through
Ant International Deepens Participation in Project Ensemble as New Architecture Community Member18.11.2025 04:00:00 CET | Press release
Ant International has been a participant in the Ensemble Sandbox since 2024 Ant International today announced it has joined Project Ensemble’s Architecture Community to support the design and advancement of Hong Kong’s tokenisation ecosystem. As a Community member, it will be more involved in defining industry standards and supporting the development of Hong Kong’s tokenisation market, together with the Hong Kong Monetary Authority (HKMA) and leading peers. A fintech representative on the Community, Ant International will also contribute its technological and innovation capabilities in tokenisation to support broader industry adoption. This comes at a time when Project Ensemble reaches a new milestone with EnsembleTX, which will see it move from sandbox experiments to live market use within a pilot environment. Through EnsembleTX, Ant International will continue to broaden its partnerships with banks and other committee members, contributing to real-world use cases of tokenisation in r
Celltrion Announces European Commission Approval of Additional Line Extension for Omlyclo™ 300mg18.11.2025 03:51:00 CET | Press release
Omlyclo™ (omalizumab) is the first and only omalizumab biosimilar approved in EuropeOmlyclo™ 300 mg/2ml prefilled syringe (PFS) presentation is now approved in EU offering a simpler dosing schedule and improved patient adherence The European Commission (EC) has granted a line extension in the European Union (EU) for Celltrion’s Omlyclo™ (omalizumab), Europe’s first and only omalizumab biosimilar, for the 300 mg/2ml prefilled syringe (PFS).The European Commission (EC) approved Omlyclo™ 75 mg/0.5ml and 150mg/1ml solution for injection in pre-filled syringe in May 2024. Omlyclo™ is indicated for the treatment of patients with allergic asthma, chronic spontaneous urticaria (CSU) and chronic rhinosinusitis with nasal polyps (CRSwNP). “The additional strength of Omlyclo™ 300mg can significantly decrease the frequency of injections, and reduce injection burden and discomfort, without compromising efficacy and safety,” said Nam Lee, Vice President of Global Medical Affairs at Celltrion. “These
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
